Ionis Pharmaceuticals (NasdaqGS:IONS) Q4 2025 Earnings call February 25, 2026 08:30 AM ET Company ParticipantsBeth Hougen - Executive VP and CFOBrett Monia - CEO, Member of the Board of Directors and Founding ScientistEric Swayze - Executive Vice President of ResearchEugene Schneider - Executive VP, Chief Clinical Development and Operations OfficerHolly Kordasiewicz - Executive VP and Chief Development OfficerKyle Jenne - Executive VP and Chief Global Product Strategy OfficerMichael Ulz - Executive Director ...

Ionis Pharmaceuticals (NasdaqGS:IONS) Q4 2025 Earnings call February 25, 2026 08:30 AM ET Company ParticipantsBrett Monia - CEO, Member of the Board of Directors and Founding ScientistElizabeth Hougen - Executive VP and CFOEric Swayze - Executive Vice President of ResearchEugene Schneider - Executive VP, Chief Clinical Development and Operations OfficerHolly Kordasiewicz - Executive VP and Chief Development OfficerKyle Jenne - Executive VP and Chief Global Product Strategy OfficerMichael Ulz - Executive Dir ...

Core Insights - Ionis Pharmaceuticals will host a live webcast on February 25, 2026, to discuss its fourth quarter and full year 2025 financial results and key program progress [1] - The company has a strong pipeline in neurology, cardiometabolic diseases, and other high-need areas, emphasizing its leadership in RNA-targeted medicines and gene editing [1] - Ionis achieved significant milestones in 2025, including two independent product launches and anticipates continued momentum and value creation in 2026 [1] Financial Results Webcast - The webcast is scheduled for February 25, 2026, at 11:30 a.m. Eastern Time [1] - A replay of the webcast will be available for a limited time [1] Company Achievements - Ionis has successfully executed its first two independent launches in 2025, marking a defining year for the company [1] - The company will provide a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] Product Approvals and Collaborations - The European Commission approved DAWNZERA™ (donidalorsen) for the prevention of hereditary angioedema in adults and adolescents aged 12 years and older [1] - Partner GSK announced positive topline results from Phase 3 studies for bepirovirsen, an investigational treatment for chronic hepatitis B, involving over 1,800 patients across 29 countries [1]

Core Points - Ionis Pharmaceuticals has received Breakthrough Therapy designation from the U.S. FDA for zilganersen, aimed at treating Alexander disease, a rare and often fatal neurological condition [1][2] - The company plans to submit a new drug application (NDA) in Q1 2026 [1][3] Company Overview - Ionis Pharmaceuticals is recognized for its innovative approach in developing treatments for serious diseases, including neurological conditions [3][9] - The company has a strong pipeline, including marketed medicines and investigational therapies, positioning it for revenue growth and value creation [3][9] Zilganersen Study Details - The pivotal study for zilganersen involved 54 participants aged 1.5 to 53 years across 13 sites in eight countries, primarily focusing on children due to the early onset of Alexander disease [4][5] - The study demonstrated a statistically significant improvement in gait speed, with a mean difference of 33.3% (p=0.0412) at week 61 for the 50 mg dose compared to control [2][5] Alexander Disease (AxD) Insights - Alexander disease affects approximately 1 in 1 to 3 million people globally and is characterized by progressive neurological deterioration, leading to loss of mobility and independence [7] - There are currently no approved disease-modifying treatments for Alexander disease, highlighting the significance of zilganersen's potential [7][6]

Core Insights - Ionis Pharmaceuticals has been recognized as the 2 top employer in the biopharmaceutical industry by Science magazine in its first year of eligibility, highlighting its industry-leading innovation and strong company culture [1][2][3] Company Recognition - The ranking reflects Ionis's commitment to scientific excellence, alignment of company and employee values, and a culture of respect, as indicated by the results of approximately 5,500 completed surveys [2][3] Leadership Commentary - The CEO of Ionis, Brett P. Monia, emphasized that the recognition showcases the caliber of their science and the unique spirit of the company culture, driven by a passionate and inquisitive team [2][3] Company Overview - Ionis Pharmaceuticals has been a pioneer in RNA-targeted medicines for three decades, focusing on innovative therapies in neurology, cardiometabolic diseases, and gene editing [4]